Neuralink Scaling to Mass Production

This marks Neuralink’s shift from proving the implant works to proving it can be built and implanted often enough for the business to work. The key bottleneck in brain computer interfaces is not just decoding neurons, it is turning a delicate implant, custom chips, and a surgical robot into repeatable hardware that can support multiple patients per month. Neuralink’s growing implant cadence and manufacturing hiring show that the company is starting to build that operational muscle.1 2 3 4

• Neuralink said five people were using its implant as of June 2, 2025, then described growth from three participants in 2024 to multiple participants per month in 2025. That kind of cadence requires more than lab style assembly, it requires standardized build, test, sterilization, and field support.1 2
• The competitive contrast is clearest with Precision Neuroscience and Synchron. Precision built a 22,000 square foot MEMS facility and reported yields above 90 percent for its surface arrays. Synchron designed around existing cath lab workflows to avoid specialized robot driven surgery. Neuralink is betting that tighter control of implant, robot, and software can eventually outweigh its more complex procedure.5 6
• The financing fits the manufacturing story. Neuralink raised $650M in June 2025 and reached an estimated $9.65B valuation by the 2025 Series E. In this category, new capital does not just fund research, it funds production equipment, quality systems, clinical operations, and the people needed to move from one off builds to repeatable output.1 3

From here, the winner in BCI will be the company that turns a hard neurosurgery product into something hospitals can schedule routinely and pay for repeatedly. If Neuralink keeps increasing implant volume while improving robot throughput and device manufacturability, its long term path to much lower device and procedure costs becomes far more realistic.2 5 6